Prostate Cancer Research
Progress Report: Howard Scher, MD
Principal Investigators: Howard Scher, MD; Charles Sawyers, MD; Neal Rosen, MD, PhD; Steve Larson, MD
Memorial Sloan-Kettering Cancer Center
The Androgen Axis in Prostate Cancer
- Advanced anti-androgen MDV3100 into Phase III clinical trials and showed that CTC enumeration may predict which patients are benefitting from MDV3100 and which are not.
- Planned a Phase I trial for a novel anti-androgen ARN509 which in preclinical studies showed increased potency and activity compared to MDV3100 – especially in settings of advanced androgen independent prostate cancer.
- Established a plan with the FDA to qualify CTC analysis in clinical trials as a surrogate endpoint for survival. This would translate into accelerated drug development because clinical trials wouldn’t have to wait for survival as an endpoint.
- Developed a new MDV3100 combination therapy with targeted agents against the cancer-promoting ATK-1 signaling pathway.